A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity of Hantaan/Puumala Virus DNA Vaccine Administered to Healthy Adult Volunteers Using the TDS-IM Electroporation Delivery Device for Prevention of Haemorrhagic Fever With Renal Syndrome

Trial Profile

A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity of Hantaan/Puumala Virus DNA Vaccine Administered to Healthy Adult Volunteers Using the TDS-IM Electroporation Delivery Device for Prevention of Haemorrhagic Fever With Renal Syndrome

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs PWRG-HTN-M(co)/pWRG-PUUV-M(s2) (Primary)
  • Indications Hantaan virus infections; Puumala virus infections; Viral haemorrhagic fevers
  • Focus Pharmacodynamics
  • Most Recent Events

    • 28 Mar 2017 Planned End Date changed from 1 May 2018 to 1 Dec 2017.
    • 28 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 25 Aug 2016 Planned End Date changed from 1 May 2016 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top